

Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina

Amanda Brechko, Michael R. Jiroutek, Kyla Jones, Bonnie Brenseke, Donald C. Maharty, James Cappola, Stephen P. Holly

BACKGROUND Some patients with COVID-19 develop life-threatening thrombotic complications including myocardial infarction, deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and ischemic stroke. These inflammatory and hypercoagulable states have been well documented in patient cohorts from metropolitan areas, but not in more rural populations, nor has a data-driven treatment plan been developed for thrombotic COVID-19 patients.

METHODS We undertook a retrospective case-control study of COVID-19-positive patients to analyze the impact of thrombosis on various clinical endpoints including terminal diagnosis and disease severity. Prevalence and impact of thrombosis were determined using medical records from 2237 COVID-19-positive patients hospitalized in Cumberland County, North Carolina. Odds ratios for terminal diagnosis, death, ICU admission, and ventilation were calculated based on thrombosis status, D-dimer level, or type of antithrombotic treatment.

RESULTS Terminal diagnosis [OR 1.81; 95% CI (1.10, 2.98)], ICU admission [2.25; (1.33, 3.81)], and ventilation [2.46; (1.45, 4.18)] were all more likely in thrombotic patients (N = 97) compared to nonthrombotic patients (N = 2140) after adjusting for age. D-dimer levels were associated with death overall, but not among thrombotic patients. Treatments that combined antiplatelet and anticoagulant drugs appeared to be more efficacious than anticoagulants alone in preventing death and severe disease.

LIMITATIONS Patient medical history prior to hospitalization was not evaluated.

CONCLUSION In this cohort, those with thrombosis are at increased risk for adverse outcomes including death and severe disease. Anti-thrombotic therapy that includes antiplatelet drugs provides improved outcomes. Higher-powered prospective trials will be necessary to confirm any potential merits of antiplatelet therapy.

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a high incidence of thrombotic complications [1–3]. The pathogenesis of SARS-CoV-2 leading to thrombosis involves an aggressive inflammatory response known as the cytokine storm, endothelial cell injury, and activation of platelets and clotting factors, resulting in a hypercoagulable state [3]. An autopsy study of patients who died of acute respiratory distress syndrome (ARDS) in the setting of COVID-19 early in the pandemic revealed that COVID-19 patients had a 9-fold greater prevalence of alveolar capillary microthrombi compared to patients who died of ARDS in the setting of influenza [4]. An indicator of this inflammatory and hypercoagulable state is thought to be elevated levels of D-dimer, a degradation product of cross-linked fibrin [1, 5, 6].

In response to the potential for thrombosis in patients with COVID-19, both prophylactic (low) and therapeutic (high) doses of antithrombotic drugs have been administered. Antithrombotic drugs are divided into 3 classes—anticoagulants, antiplatelets, and fibrinolytics—each having a distinct mechanism of action. Fibrinolytics act to dissolve existing clots, whereas anticoagulants and antiplatelets prevent thrombosis by inhibiting clotting factors of the coagulation cascade or platelet aggregation, respectively [7, 8].

Recent guidelines recommend prophylactic doses of anticoagulants such as heparin for the management of COVID-19 based on trials with both prophylactic and therapeutic anticoagulation treatment arms [9, 10]. For example, a recent trial of therapeutic anticoagulation with heparin in non-critically ill patients with COVID-19 showed that therapeutic anticoagulation with heparin is associated with a greater probability of survival, hospital discharge, and a greater number of days free of cardiovascular or respiratory organ support compared to prophylactic anticoagulation with heparin [11]. In contrast, trials using similar treatments (therapeutic anticoagulation with heparin) in critically ill patients with COVID-19 did not demonstrate a survival benefit [12, 13]. The role of fibrinolytics and antiplatelet agents as treatments for COVID-19 is not yet clear, but several clinical trials with antiplatelet drugs, such as aspirin and clopidogrel are ongoing (NCT04409834, NCT04424901, and NCT04505774) [14].

Electronically published September 22, 2022.

Address correspondence to Stephen P. Holly, Department of Pharmaceutical and Clinical Sciences, College of Pharmacy & Health Sciences, Campbell University, PO Box 1090, 205 Day Dorm Rd, Buies Creek, NC 27506 (sholly@campbell.edu).

N C Med J. 2023;84(2):127-133. ©2023 by the North Carolina Institute of Medicine and The Duke Endowment. All rights reserved. 0029-2559/2023/84201

Minority and rural populations experience greater risk for severe COVID-19 illness and mortality and appear underrepresented in COVID-19 research [15]. In the context of these findings, we sought to analyze the incidence of thrombotic complications among the largely rural population of Cumberland County, North Carolina, and surrounding area, which is home to few major urban centers [16]. Fayetteville is the largest city within this region and is home to Cape Fear Valley Medical Center, a 678-bed tertiary care hospital. Therefore, the goal of this study was to analyze patient records from the Cape Fear Valley Medical Center to: 1) determine the prevalence and impact of thrombosis in patients with COVID-19 in rural areas of North Carolina and 2) identify potential interventions associated with improved outcomes in this patient population.

Methods

This retrospective case-control study utilized deidentified records collected from 2237 patients at the Cape Fear Valley Medical Center in Fayetteville, North Carolina, from March 2020 to January 2021. This research was approved as an exempt protocol by the IRB of the Cape Fear Valley Medical Center (protocol #326-20) prior to data collection. Data included demographic characteristics, discharge disposition, thrombosis, antithrombotic drug treatment, ICU admission, ventilation, and terminal diagnosis, which was defined as either death or hospice care utilization. We created binary (yes/no) variables for the primary endpoints of terminal diagnosis, death, ICU admission, ventilation, and receipt of any medication (heparin, enoxaparin, warfarin, apixaban, rivaroxaban, clopidogrel, ticagrelor, and prasugrel), anticoagulant medication (heparin, enoxaparin, warfarin, apixaban, and rivaroxaban), and antiplatelet medication (clopidogrel, ticagrelor, and prasugrel). Based on literature values, we defined a high/low D-dimer variable (2 µg/mL).

A number of patients had multiple records in the dataset (corresponding to multiple hospital visits within the study period). Out of the 2727 records in the original data from 2237 patients, 490 visits were distributed across 375 patients with a range of 2–7 records per patient. In an attempt to eliminate bias and make those with multiple records comparable to those with just a single record, we created a set of rules (without inspecting the data). For each patient with multiple records: 1) any incidence of death, hospice care, ICU admission, or thrombosis was counted and retained; 2) medications from only the most recent admission date were counted in the single row, which was retained (medications from all other rows were excluded); and 3) D-dimer values from a patient's initial (oldest) visit were retained (D-dimer values from all other rows were excluded).

Multivariable logistic regression models were constructed to evaluate the relationship between thrombosis and each outcome of terminal diagnosis, ICU admission, and ventilation. Age was included as a predictor variable in

each model to account for concerns over any confounding between thrombosis and age. Odds ratios (OR) and associated 95% confidence intervals (CIs), adjusted for the inclusion of age in each model, were reported.

Computation of unadjusted ORs and 95% CIs permitted an assessment of the strength of the relationship between 1) terminal diagnosis and various medication use as well as ICU admission and various medication use (any medication, anticoagulant medication, and antiplatelet medication); 2) death or ICU admission and D-dimer level (low versus high) overall as well as amongst those with only thrombosis; and 3) death or ICU admission and (combined) thrombosis and high D-dimer level (both versus not both).

We conducted 2 sample independent group t-tests to compare the mean D-dimer values for those with and without thrombosis. Subjects missing data were excluded only from analyses for which the data were missing. As this was an exploratory, hypothesis-generating type of study, no adjustments for multiple comparisons were made. In addition, following current thinking regarding best practices for significance testing, *P*-values were reported as appropriate, but statistical significance was not evaluated for any results [17]. All analyses were generated using SAS version 9.4 or JMP version 14.

Results

The purpose of this retrospective single-site study was to identify potential associations between COVID-19 and thrombosis with respect to patient outcome, antithrombotic strategies, and disease severity in a hospitalized population from a rural demographic. To evaluate the association of thrombosis with these factors, 2237 patients were divided into 2 groups for further analysis: case (COVID + thrombosis, *n* = 97) and control (COVID-19 alone, *n* = 2140). All 2237 patients were SARS-CoV-2 positive, predominantly female (52.9%), and mostly identified as either African American (52.1%) or White (32.7%, Table 1). The Cape Fear Valley ICU admitted a relatively low number of patients (8.6%) from our cohort and a similar number received ventilation treatment (7.8%). Only 97 COVID-19-positive patients were diagnosed with cardiovascular or cerebrovascular thrombosis (4.3%) as defined by clinical evaluation and diagnosis-related group (DRG) codes. However, 20.6% of those needing intensive care were diagnosed with thrombosis (Table 1). Overall, patients experienced a variety of outcomes, with the vast majority surviving and discharged to home (1611, 72.0%), whereas 247 patients (11.1%) expired or received hospice care. Patients who left against medical advice or were discharged to long-term care collectively represented 2.0% of the total population studied (Table 1).

Impact of Thrombosis

To evaluate the impact of thrombosis on patient outcomes and epidemiology, odds of terminal diagnosis (death or hospice), ICU admission, and initial D-dimer levels in

TABLE 1.
Patient Demographics and Selected Thrombosis Parameters

	COVID-19 only n = 2140 (%)	COVID-19+thrombosis n = 97 (%)	Total N = 2237 (%)
Age in years (Mean $\pm$ SD)	52.5 $\pm$ 23.8	70.2 $\pm$ 16.1	53.2 $\pm$ 23.8
Gender			
Female	1144 (53.5)	40 (41.2)	1184 (52.9)
Male	996 (46.5)	57 (58.8)	1053 (47.1)
Ethnicity			
African American	1117 (52.3)	46 (47.9)	1163 (52.1)
White	698 (32.7)	33 (34.4)	731 (32.7)
Remaining	323 (15.1)	17 (17.7)	340 (15.2)
ICU admission	173 (8.1)	20 (20.6)	193 (8.6)
Ventilator treatment	154 (7.2)	20 (20.6)	174 (7.8)
Terminal diagnosis ^b	220 (10.3)	27 (27.8)	247 (11.1)
Discharged to home	1572 (73.5)	39 (40.2)	1611 (72.0)
Left against medical advice	29 (1.4)	3 (3.0)	32 (1.4)
Discharged to long-term care	9 (0.4)	4 (4.1)	13 (0.6)

SD: Standard Deviation; ICU: Intensive Care Unit

^aPercentages are slightly elevated due to three missing data points.

^bTerminal diagnosis includes death and discharged to hospice.

thrombotic (case) and nonthrombotic COVID-19 patients (control) were analyzed. Over 80% of thrombotic patients were aged 56 years or over, with the highest fraction of thrombosis occurring in patients over age 75, at 45.4% (Figure 1A). Reflective of the total COVID-19-positive patient population in this study, 47.9% of thrombotic patients were African American, followed by 34.4% who were White, with the remaining 17.7% of other ethnicities (Figure 1B).

Thrombosis in combination with COVID-19 was associated with a higher risk of terminal diagnosis compared to patients with COVID-19 alone after adjusting for age (OR 1.81, 95% CI 1.10–2.97, Table 2). In addition, patients with thrombosis were more likely to be admitted to the ICU (OR 2.25, 95% CI 1.33–3.81, Table 2) or placed on a ventilator (OR 2.46, 95% CI 1.45–4.18, Table 2). These data indicate that a combination of thrombosis and SARS-CoV-2 infection greatly influences patient outcome with respect to increased


probability of mortality and severity of disease, even after accounting for age in each model.

D-dimer

Despite this strong correlation between thrombosis and adverse outcomes, levels of the clot biomarker D-dimer only weakly correlated with thrombosis. As shown in Figure 2, among 1176 patients who underwent laboratory-confirmed D-dimer testing, the mean D-dimer value for 62 thrombotic patients was 4.0 ± 6.52 $\mu\text{g/mL}$ compared to 2.24 ± 3.82 $\mu\text{g/mL}$ for 1114 patients without thrombosis (Figure 2, $P = .04$).

To further analyze D-dimer levels, a “high” D-dimer value was derived from the literature (≥ 2 $\mu\text{g/mL}$) and used as a threshold value to assess the association between D-dimer level (high, ≥ 2 $\mu\text{g/mL}$ versus low, < 2 $\mu\text{g/mL}$) and death. High D-dimer was associated with an increased risk of death irrespective of thrombosis (OR 2.92, 95% CI 2.09–4.10,

FIGURE 1.
Distribution of Patients with Thrombosis According to Age (A) or (B) Ethnicity



Thrombosis incidence was calculated as a percentage of patients within the indicated age ranges (A) or ethnicity (B). Only data for thrombotic patients are shown for both panels (n = 97). Thrombosis across ethnicity closely mimicked the racial distribution of the entire patient population (N = 2237).

TABLE 2.
Odds Ratios (95% CI) of Terminal Diagnosis or Death, ICU Admission, or Ventilation by Thrombosis or D-dimer Value

Endpoint	Thrombosis ^a	D-dimer ^b	D-dimer ^c
Terminal diagnosis ^d	1.81 (1.10–2.97)	ND	ND
Death	-	2.92 (2.09–4.01)	0.88 (0.28–2.78)
ICU	2.25 (1.33–3.81)	2.40 (1.69–3.42)	1.97 (0.63–6.17)
Ventilation	2.46 (1.45–4.18)	-	-

OR: Odds Ratio; CI: Confidence Interval; ND: not determined

^aOR (95% CI) from multivariable logistic regression models to compare each endpoint for those with thrombosis to those with no thrombosis, adjusting for patient age, while using the entire patient population, N = 2237.

^bOR (95% CI) comparing death for all those with high D-dimer levels to all those with low D-dimer levels, n = 1176.

^cOR (95% CI) comparing death for those with high D-dimer levels to those with low D-dimer levels in thrombotic patients only, n = 62.

^dTerminal diagnosis includes death and discharged to hospice.

Table 2). However, the risk of death within the thrombotic case population alone was not found to be associated with D-dimer level (OR 0.88, 95% CI 0.28–2.78, n = 62, Table 2) nor did the combination of thrombosis and high D-dimer level associate with increased risk of death within the total population (data not shown). Collectively, our data show a weak correlation between thrombosis and high D-dimer level despite the similar maximum D-dimer values for thrombotic and nonthrombotic COVID-19 patients. High D-dimer value correlates more strongly with death in the total population, which is driven by the higher number of nonthrombotic COVID-19 patients in this cohort.


Antithrombotic Treatment

In an effort to determine which anticoagulant treatment strategies were associated with positive outcomes, odds of

terminal diagnosis and ICU admission were calculated in patients given anticoagulant medications. Antithrombotics were broadly defined as either anticoagulant (heparin, enoxaparin, warfarin, apixaban, and rivaroxaban) or antiplatelet (P2Y12 antagonists: clopidogrel, ticagrelor, and prasugrel) medications. Over 61% of all patients and 91.8% of thrombotic patients received at least 1 anticoagulant or antiplatelet medication. The majority of thrombotic patients received anticoagulants (55.7%) as opposed to antiplatelet drugs alone (1.0%) or a combination of both (35.1%).

Admission to the ICU indicated disease severity. Patients receiving at least 1 antithrombotic drug were more likely to be admitted to the ICU (OR 10.54, 95% CI 5.84–19.04, Table 3). Patients receiving an antiplatelet drug (as compared to those who received none) were also more likely to arrive in

FIGURE 2.
Distribution of D-dimer Values in Thrombotic and Nonthrombotic COVID-19 Patients



Lab-confirmed D-dimer tests for 1114 nonthrombotic patients (mean $\pm$ SD, 2.24 ± 3.82 $\mu\text{g/mL}$) and for 62 patients diagnosed with thrombosis (mean $\pm$ SD, 4.0 ± 6.52 $\mu\text{g/mL}$) were plotted. The limited number of patients with thrombosis makes comparisons of the 2 distributions of D-dimer values potentially spurious.

TABLE 3.
Odds Ratios (95% CI) of Terminal Diagnosis or ICU Admission by Type of Antithrombotic Treatment

Endpoint	All meds ^a	Anticoagulant ^b	Antiplatelet ^c
Terminal diagnosis	12.13 (7.02–20.96)	12.33 (7.14–21.30)	2.30 (1.52–3.48)
ICU	10.54 (5.84–19.04)	10.70 (5.94–19.30)	1.88 (1.17–3.03)

OR: Odds Ratio; CI: Confidence Interval

^aOR (95% CI) comparing each endpoint for those treated with any medication to those treated with none, N = 2237.

^bOR (95% CI) comparing each endpoint for those treated with at least one anticoagulant to those treated with none (see Methods), N = 2237.

^cOR (95% CI) comparing each endpoint for those treated with at least one antiplatelet to those treated with none (see Methods), N = 2237.

the ICU (OR 1.88, 95% CI 1.17–3.03, N = 2237, Table 3) but with relatively lower odds.

Similarly, odds of terminal diagnosis (defined as in-hospital death or discharged to hospice care) for patients receiving at least 1 type of antithrombotic medication as compared to those receiving none, regardless of thrombotic status, was very high (OR 12.13, 95% CI 7.02–20.96, Table 3). Patients receiving at least 1 anticoagulant (as compared to those receiving none) experienced high odds of terminal diagnosis (OR 12.33, 95% CI 7.14–21.30, Table 3). Interestingly, the odds of terminal diagnosis in patients receiving at least 1 antiplatelet medication compared to patients receiving no antiplatelet medications (anticoagulants alone) was relatively low (OR 2.30, 95% CI 1.52–3.48, Table 3). Furthermore, of the 23 thrombotic patients who died, 60.9% were treated only with anticoagulants, whereas 39.1% were treated with both anticoagulant and antiplatelet drugs, and none were treated with antiplatelet drugs alone. These outcomes likely reflect severity of disease, as we have no reason to believe medication(s) directly contributed to morbidity or mortality.

Discussion

Patients with COVID-19 hospitalized at Cape Fear Valley Medical Center had a 4.3% incidence of thrombosis. Compared to other studies focused on thrombosis in COVID-19 patients, this incidence appears low. Among COVID-19 patients hospitalized at the nearby Duke University Health System, 12.0% experienced a thromboembolic event [18], and among 3334 hospitalized COVID-19 patients in New York, the thrombosis incidence was 16.0% [1]. Thrombotic events in COVID-19 patients in the ICU setting, however, were comparable between our cohort (20.6%) and populations from large urban areas or multicenter studies, which ranged from 6.3% to 31% [5, 13, 19–21].

Over 80% of thrombotic patients in our study were aged 56 years or over, with the highest fraction of thrombosis occurring in patients aged over 75, which is consistent with existing data [22]. This increased risk for severe disease in older patients could be due to increased susceptibility to the virus, the presence of comorbidities, and naturally waning immunity [23, 24]. Comparing census data for Cumberland County to our study cohort, a disproportionately large percentage of the patients were African American [25]. Other

studies have observed a disproportionate incidence of COVID-19 among racial minority groups, which may reflect differences in housing, work environments, or underlying medical comorbidities [15, 26].

While patients in this study had a relatively low incidence of thrombosis, patients with thrombosis were more likely to have severe disease (ICU admission) or require ventilation treatment. Additionally, those with documented thrombotic events were at higher risk of terminal diagnosis (death or hospice) compared to patients with COVID-19 alone. These data indicate that COVID-19-associated thrombosis greatly influences patient outcome with respect to increased probability of mortality and severity of disease and are consistent with other studies [21, 27].

Although considered a feature of COVID-19-associated coagulopathy, an elevated D-dimer level in our patient population only weakly correlated with thrombosis. In fact, both case and control populations in our study exhibited “high” (≥ 2 $\mu\text{g/mL}$) mean D-dimer concentrations and were not statistically different. It is well known that elevated D-dimer concentrations are observed in many thrombotic disease states, such as pulmonary embolism and deep vein thrombosis, but do not always indicate thrombosis since D-dimer values may be elevated in nonthrombotic conditions, such as pregnancy, trauma, infection, liver disease, and malignancy [28, 29]. However, an extremely elevated D-dimer is uniquely associated with severe disease including venous thromboembolism, sepsis, cancer, and now COVID-19 [1, 5, 30, 31]. Elevated D-dimer levels also correlated with severe disease in our patient cohort, manifested by increased odds of death, which suggests that abnormally elevated D-dimer levels serve more as a general predictor of a negative patient outcome than as a specific marker for thrombosis [30, 32, 33].

Despite patient demographics, disease severity, or a clear diagnosis of thrombosis, initiation of antithrombotic medications is becoming the standard of care for hospitalized COVID-19 patients. Heparin is the prototypical prophylactic anticoagulant used for most hospitalized patients and has been globally recommended as a treatment for COVID-19; however, some studies show therapeutic doses of heparin are insufficient for reversing the hypercoagulable state induced by COVID-19 [12, 13].

In addition to coagulation, platelet hyperreactivity contributes to the thrombotic sequelae of COVID-19. For example, multiple groups have shown that platelets isolated from COVID-19 patients have a procoagulant or hyperreactive phenotype in which platelets secrete higher levels of activation markers such as P-selectin, aggregate more intensely in response to agonists, and generate more leukocyte-containing aggregates compared to controls [34–38]. Other studies have revealed that platelet development, secretion, and regulation of normal blood clotting (hemostasis) are critical pathways affected by COVID-19 [39–41]. Consistent with these data, the use of antiplatelet drugs in COVID-19 patients appears to improve patient outcomes and respiratory symptoms. For example, aspirin treatment correlates with reduced all-cause mortality and severity of COVID-19 symptoms [42] and fondaparinux treatment in combination with aspirin, clopidogrel, and tirofiban leads to increased arterial oxygen partial pressure and reduced hypoxemia [43].

Despite these encouraging results, data regarding efficacy of antiplatelet strategies in COVID-19 remain scarce. Interestingly, patients in our study who received at least 1 antiplatelet medication compared to those receiving no antiplatelet medications (anticoagulants alone or no medications) experienced a lower risk of death and discharge to hospice care. These data indicate that anticoagulants used in this patient population only partially mitigated the odds of death or severe disease and suggest that antiplatelet drugs or a combination of anticoagulant and antiplatelet medications may be more effective treatment options compared to anticoagulants alone. Furthermore, of the thrombotic patients who died, 60.9% were treated only with anticoagulants, whereas 39.1% were treated with both anticoagulants and antiplatelet drugs, suggesting that targeting platelet activation may be beneficial for certain COVID-19 patients. In fact, another group recently identified prior antiplatelet therapy as a beneficial factor for COVID-19 outcome [44]. As of this writing, there are several ongoing clinical trials investigating efficacy of anticoagulant, antiplatelet, and combinations of both in patients with COVID-19 (e.g., NCT04324463, NCT04359277, NCT04409834, NCT04424901, and NCT04505774).

A limitation of this study is the lack of medication and health history prior to hospitalization, as antithrombotic treatments and comorbidities could potentially impact outcomes and interpretation of the data. Due to the retrospective design of this study, however, it is not possible to demonstrate causal relationships between disease states and mortality, nor between therapeutic interventions and improved patient outcomes; retrospective analysis can only identify association, not causation. However, our results are consistent with another recently published retrospective antiplatelet analysis, which suggests that retrospective study designs may be valuable for identifying associations in COVID-19 patient populations [44].

In conclusion, our study addresses an unmet need

by evaluating the impact of thrombosis in patients with COVID-19 from rural communities and by identifying potential interventions that may benefit this patient population. The overall incidence of thrombotic complications in this cohort is relatively low, but as with other populations in more urban settings, thrombosis was associated with increased mortality and COVID-19 disease severity. Importantly, the combination of anticoagulant and antiplatelet drugs greatly lowered the odds of death and severe disease, suggesting that the addition of antiplatelet drugs to an antithrombotic treatment regimen for hospitalized COVID-19 patients may be an effective therapeutic option. Higher-powered prospective trials will be necessary to confirm our observations and the potential merits of antiplatelet therapy in these patients. **NCMJ**

Amanda Brechko, BS Campbell University, Buies Creek, North Carolina.
Michael R. Jiroutek, DrPH associate professor, Pharmaceutical & Clinical Sciences and adjunct associate professor, Pharmacy Practice, College of Pharmacy & Health Sciences, Campbell University, Buies Creek, North Carolina.

Kyla Jones, MS Jerry M. Wallace School of Osteopathic Medicine, Campbell University, Buies Creek, North Carolina.

Bonnie Brenseke, DVM, PhD associate professor and biomedical chair of pathology, Jerry M. Wallace School of Osteopathic Medicine, Campbell University, Buies Creek, North Carolina.

Donald C. Maharty, DO regional associate dean, Family Medicine, Jerry M. Wallace School of Osteopathic Medicine, Campbell University, Buies Creek, North Carolina; vice president, Medical Education, Cape Fear Valley Medical Center, Fayetteville, North Carolina.

James Cappola, MD chair and associate professor of internal medicine, Jerry M. Wallace School of Osteopathic Medicine, Campbell University, Buies Creek, North Carolina.

Stephen P. Holly, PhD associate professor, Pharmaceutical & Clinical Sciences, College of Pharmacy & Health Sciences and IRB chair, Office of the Provost, Campbell University, Buies Creek, North Carolina.

Acknowledgments

All authors contributed to the writing of the manuscript. AB, BB, DCM, JC, and SPH created the experimental design. MRJ performed statistical analysis. AB, SPH, and DCM wrote the IRB. DCM acquired medical records. MRJ and SPH made figures.

This work was supported by the Honors College of Campbell University (AB), College of Pharmacy and Health Sciences, Department of Pharmaceutical Sciences and Clinical Research at Campbell University (MRJ, SPH), and the School of Osteopathic Medicine at Campbell University (KJ, BB, DCM, JC).

The authors declare no conflicts of interest.

References

1. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. *JAMA*. 2020;324(8):799–801. doi: 10.1001/jama.2020.13372
2. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications. *Circ Res*. 2020;127(4):571–587. doi: 10.1161/CIRCRESAHA.120.317447
3. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. *Front Immunol*. 2020;11:1446. doi: 10.3389/fimmu.2020.01446
4. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med*. 2020;383(2):120–128. doi: 10.1056/NEJMoa2015432
5. Berger JS, Kunichoff D, Adhikari S, et al. Prevalence and outcomes of D-dimer elevation in hospitalized patients with COVID-19. *Arterioscler Thromb Vasc Biol*. 2020;40(10):2539–2547. doi: 10.1161/ATVBAHA.120.314872
6. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associ-

- ated with the severity of COVID-19. *Thromb Res.* 2020;195:219-225. doi: 10.1016/j.thromres.2020.07.047
7. Jamasbi J, Ayabe K, Goto S, Nieswandt B, Peter K, Siess W. Platelet receptors as therapeutic targets: past, present and future. *Thromb Haemost.* 2017;117(7):1249-1257. doi: 10.1160/TH16-12-0911
8. Gross PL, Weitz JI. New antithrombotic drugs. *Clin Pharmacol Ther.* 2009;86(2):139-146. doi: 10.1038/clpt.2009.98
9. Thachil J, Juffermans NP, Ranucci M, et al. ISTH DIC subcommittee communication on anticoagulation in COVID-19. *J Thromb Haemost.* 2020;18(9):2138-2144. doi: 10.1111/jth.15004
10. Cuker A, Tseng EK, Nieuwlaar R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. *Blood Adv.* 2021;5(3):872-888. doi: 10.1182/bloodadvances.2020003763
11. Investigators A, Investigators AC-a, Investigators R-C, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. *N Engl J Med.* 2021;385(9):790-802. doi: 10.1056/NEJMoa2105911
12. Investigators R-C, Investigators AC-a, Investigators A, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. *N Engl J Med.* 2021;385(9):777-789. doi: 10.1056/NEJMoa2103417
13. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood.* 2020;136(4):489-500. doi: 10.1182/blood.2020006520
14. Matli K, Farah R, Maalouf M, Chamoun N, Costanian C, Ghanem G. Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review. *Open Heart.* 2021;8(1):e001628. doi: 10.1136/openhrt-2021-001628
15. Cheng KJG, Sun Y, Monnat SM. COVID-19 death rates are higher in rural counties with larger shares of Blacks and Hispanics. *J Rural Health.* 2020;36(4):602-608. doi: 10.1111/jrh.12511
16. Health Statistics and Data. North Carolina Department of Health and Human Services website. Published 2021. Accessed November 1, 2021. <https://www.ncdhhs.gov/divisions/office-rural-health/office-rural-health-programs/analytics-and-innovations-program/health-statistics-and-data>
17. Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond "p<0.05". *The American Statistician.* 2019;73(Suppl 1):1-19. <https://doi.org/10.1080/00031305.2019.1583913>
18. Daugherty MM, Morgan A, Frost E, et al. COVID-19 associated coagulopathy: thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. *Thromb Res.* 2020;196:483-485. doi: 10.1016/j.thromres.2020.10.004
19. Al-Samkari H, Gupta S, Leaf RK, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. *Ann Intern Med.* 2021;174(5):622-632. doi: 10.7326/M20-6739
20. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(6):1421-1424. doi: 10.1111/jth.14830
21. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res.* 2020;191:145-147. doi: 10.1016/j.thromres.2020.04.013
22. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(15):458-464. doi: 10.15585/mmwr.mm6915e3
23. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. *J Infect.* 2020;80(6):656-665. doi: 10.1016/j.jinf.2020.03.041
24. Davies J. The coronavirus pandemic has forced rapid changes in care protocols for cystic fibrosis. *Nature.* 2020;583(7818):S15. doi: 10.1038/d41586-020-02112-y
25. QuickFacts: Cumberland County, North Carolina. US Census Bureau website. Updated July 1, 2021. Accessed September 20, 2021. <https://www.census.gov/quickfacts/cumberlandcountynorthcarolina>
26. Killerby ME, Link-Gelles R, Haight SC, et al. Characteristics associated with hospitalization among patients with COVID-19 - metropolitan Atlanta, Georgia, March - April 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(25):790-794. doi: 10.15585/mmwr.mm6925e1
27. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. *Lancet Haematol.* 2020;7(8):e575-e582. doi: 10.1016/S2352-3026(20)30216-7
28. Lippi G, Bonfanti L, Saccenti C, Cervellin G. Causes of elevated D-dimer in patients admitted to a large urban emergency department. *Eur J Intern Med.* 2014;25(1):45-48. doi: 10.1016/j.ejim.2013.07.012
29. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, doctor! My D-dimer is raised. *Ann Med.* 2008;40(8):594-605. doi: 10.1080/07853890802161015
30. Schutte T, Thijs A, Smulders YM. Never ignore extremely elevated D-dimer levels: they are specific for serious illness. *Neth J Med.* 2016;74(10):443-448.
31. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in Coronavirus Disease 2019: a systematic review and meta-analysis. *Cardiol Rev.* 2020;28(6):295-302. doi: 10.1097/CRD.0000000000000330
32. Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. *Intern Med J.* 2007;37(9):607-613. doi: 10.1111/j.1445-5994.2007.01388.x
33. Schouten HJ, Geersing GJ, Koek HL, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. *BMJ.* 2013;346:f2492. doi: 10.1136/bmj.f2492
34. Althaus K, Zlmal J, Bakchoul T. Antibody-mediated platelet activation in COVID-19: a coincidence or a new mechanism of the dysregulated coagulation system? *J Thromb Haemost.* 2021;19(5):1171-1173. doi: 10.1111/jth.15275
35. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. *Blood.* 2020;136(11):1330-1341. doi: 10.1182/blood.2020007252
36. Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. *Blood.* 2020;136(11):1317-1329. doi: 10.1182/blood.2020007214
37. Yatim N, Boussier J, Chocron R, et al. Platelet activation in critically ill COVID-19 patients. *Ann Intensive Care.* 2021;11(1):113. doi: 10.1186/s13613-021-00899-1
38. Zaid Y, Guessous F, Puhm F, et al. Platelet reactivity to thrombin differs between patients with COVID-19 and those with ARDS unrelated to COVID-19. *Blood Adv.* 2021;5(3):635-639. doi: 10.1182/bloodadvances.2020003513
39. Barrett TJ, Bilaloglu S, Cornwell M, et al. Platelets contribute to disease severity in COVID-19. *J Thromb Haemost.* 2021;19(12):3139-3153. doi: 10.1111/jth.15534
40. Shu T, Ning W, Wu D, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. *Immunity.* 2020;53(5):1108-1122. doi: 10.1016/j.immuni.2020.10.008
41. Zamanian-Azodi M, Arjmand B, Razzaghi M, Rezaei Tavarani M, Ahmadzadeh A, Rostaminejad M. Platelet and haemostasis are the main targets in severe cases of COVID-19 infection; a system biology study. *Arch Acad Emerg Med.* 2021;9(1):e27. doi: 10.22037/aaem.v9i1.1108
42. Chow JH, Khanna AK, Kethireddy S, et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with Coronavirus Disease 2019. *Anesth Analg.* 2021;132(4):930-941. doi: 10.1213/ANE.0000000000005292
43. Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. *Pharmacol Res.* 2020;158:104950. doi: 10.1016/j.phrs.2020.104950
44. Chow JH, Yin Y, Yamane DP, et al. Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: a propensity score-matched analysis. *J Thromb Haemost.* 2021;19(11):2814-2824. doi: 10.1111/jth.15517